Health Care · Services-Medical Laboratories · Nasdaq · CIK 1737523 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $1.32Day −2.94%Mkt cap $24M1Y −81.6%Off 52W high −85.3%Vol (1Y) 96.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,225 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.0% of sh out |
| Days to cover1.0d |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-17 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$5.3M |
| Earnings (TTM)-$2.9M |
| ROE−35.2% |
| Net margin−40.2% |
| ROIC−40.5% |
| Sales growth 3Y−12.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−66.6% |
| 1Y−81.6% |
| 3Y−94.1% |
| 5Y−99.1% |
| Since incept. (ann.)−60.7% |
Price return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)96.3% |
| Ann. volatility (3Y)281.6% |
| Sharpe (1Y)−0.86 |
| Sharpe (3Y)0.41 |
| Max drawdown (1Y)−81.6% |
| Max drawdown (3Y)−94.1% |
| Beta (3Y vs SPY)4.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| UBS Group AG | 231 | $495 | 0.00% | new |
| WELLS FARGO & COMPANY/MN | 1 | $2 | 0.00% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.23 | — | $22,842 | −98.9% |
| 2025-12-31 | 2026-04-14 | — | — | $483,760 | −80.8% |
| 2025-09-30 | 2025-11-14 | −$0.40 | — | $2.5M | −3.3% |
| 2025-06-30 | 2025-08-18 | −$0.34 | −403.5% | $2.3M | +14.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-17 is ESTIMATED from filing cadence (median gap 94d) — not company-confirmed.
MY 79% · MV 9% · LK 6% · SG 3% · ID 2%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
